REFERENCES

1.    Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. Journal of Nuclear Medicine 2001; 42:1S-93S.

2.  Hendee WR. Teaching Physics to Radiology Residents. American Journal of Roentgenology 2009; 192:855-858.

3. Magill J, Galy J. Radioactivity Radionuclides Radiation. 1st ed. Berlin/Heidelberg: Springer-Verlag; 2005.

4.    Jadvar H, Parker JA. Clinical PET and PET/CT. 1st ed. London: Springer-Verlag; 2005.

5. Groch MW. The AAPM/RSNA physics tutorial for residents - Radioactive decay. Radiographics 1998; 18:1247-1256.

6.  Votaw JR.The AAPM/RSNA Physics Tutorial for Residents Physics of PET. Radiographics 1995; 15:1179-1190.

7.    Zanzonico P, Heller S. Physics, Instrumentation, and Radiation Protection. In: Biersack H-J, Freeman LM, eds. Clinical Nuclear Medicine. 1st ed. Berlin, Heidelberg: Springer Berlin Heidelberg; 2007:1-33.

8.    Bailey DL, Karp JS, Surti S. Physics and Instrumentation in PET. In: Bailey DL, Townsend DW, Valk PE, Maisey MN, ed. Positron Emission Tomography. 1st ed. London: Springer-Verlag; 2005:13-40.

9.    Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24:523-543.

10.  Ranger NT. Radiation detectors in nuclear medicine. Radiographics 1999; 19:481-502.

11.  Shiue CY, Welch MJ. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose. Radiologic Clinics of North America 2004; 42: 1033 – 1053.

12.  Altamirano Ley J, Estrada Sánchez G. Tomografía Por Emisión de Positrones Y Tomografía Computarizada: Aplicaciones Clínicas. 1st ed. Panamericana; 2013.

13.  Leung K. 2-Hydroxy-3-isobutyl-9-[11C]methoxy-10-methoxy-1,2,3,4,6,7,-hexahydro-11bH-bezo[α]-quinolizine. 2006 Mar 17 [Updated 2010 Oct 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23597/

14.  Lin SC, Lin KJ, Hsiao IT, et al. In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by F-18-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. Journal of Nuclear Medicine 2014; 55:73-79.

15.  Chan GLY, Holden JE, Stoessl AJ, et al. Reproducibility studies with C-11-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. Journal of Nuclear Medicine 1999; 40:283-289

16.  Leung K. 16α-[18F]Fluoro-17β-estradiol. 2004 Dec 6 [Updated 2008 Jun 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23239/

17.  van Kruchten M, Glaudemans A, de Vries EFJ, et al. PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. Journal of Nuclear Medicine 2012; 53:182-190.

18.  Leung K. [11C]Acetate. 2005 Dec 8 [Updated 2008 May 19]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23334/

19.  Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells. Nuclear Medicine and Biology 2001; 28:117-122.

20.  Jadvar H. Molecular Imaging of Prostate Cancer: PET Radiotracers. American Journal of Roentgenology 2012; 199:278-291.

21.  Seltzer MA, Jahan SA, Sparks R, et al. Radiation dose estimates in humans for C-11-acetate whole-body PET. Journal of Nuclear Medicine 2004; 45:1233-1236.

22.  Cheung TT, Ho CL, Lo CM, et al. C-11-Acetate and F-18-FDG PET/CT for Clinical Staging and Selection of Patients with Hepatocellular Carcinoma for Liver Transplantation on the Basis of Milan Criteria: Surgeon's Perspective. Journal of Nuclear Medicine 2013; 54:192-200.

23.  Chopra A. 68Ga-Labeled (1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid)-1-NaI3-octreotide. 2009 May 12 [Updated 2009 Jun 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23019/

24.  Maecke HR, Hofmann M, Haberkorn U. Ga-68-labeled peptides in tumor imaging. Journal of Nuclear Medicine 2005; 46:172S-178S

25.  Prasad V, Ambrosini V, Alavi A, Fanti S, Baum RP. PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clinics 2008;3(3):355-379.

26.  Kagna O, Pirmisashvili N, Tshori S, Freedman N, Israel O, Krausz Y. Neuroendocrine Tumor Imaging with Ga-68-DOTA-NOC: Physiologic and Benign Variants. American Journal of Roentgenology 2014; 203:1317-1323.

27.  Naswa N, Sharma P, Kumar A, et al. Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study. American Journal of Roentgenology 2011; 197:1221-1228

28.  Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Somatostatin Receptor-Based PET/CT of Intracranial Tumors: A Potential Area of Application for Ga-68-DOTA Peptides? American Journal of Roentgenology 2013; 201:1340-1347.

29.  Bastawrous S, Bhargava P, Behnia F, Djang DSW, Haseley DR. Newer PET Application with an Old Tracer: Role of F-18-NaF Skeletal PET/CT in Oncologic Practice. Radiographics 2014; 34:1295-1316.

30.  Mick CG, James T, Hill JD, Williams P, Perry M. Molecular Imaging in Oncology: F-18-Sodium Fluoride PET Imaging of Osseous Metastatic Disease. American Journal of Roentgenology 2014; 203:263-271.

31.  Drubach LA, Connolly SA, Palmer EL. Skeletal Scintigraphy With F-18-NaF PET for the Evaluation of Bone Pain in Children. American Journal of Roentgenology 2011; 197:713-719.

32.  The MICAD Research Team. [18F]Fluoromisonidazole. 2005 Jul 18 [Updated 2005 Aug 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23099/.

33.  Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: Evaluation by F-18 fluoromisonidazole and F-18 fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research 2004; 10:2245-2252.

34.  Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. Journal of Nuclear Medicine 2008; 49:129S-148S.

35.  Cheng JY, Lei L, Xu JY, et al. F-18-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer. Journal of Nuclear Medicine 2013; 54:333-340.

36.  Leung K. [11C]Choline. 2004 Oct 1 [Updated 2011 Feb 7]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23549/

37.  Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2014; 41:11-20

38.  Tehrani OS, Shields AF. PET Imaging of Proliferation with Pyrimidines. Journal of Nuclear Medicine 2013; 54:903-912

39.  Leung K. 3'-Deoxy-3'-[18F]fluorothymidine. 2004 Oct 1 [Updated 2005 Jan 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23373/

40.  Cannon DM, Kruser TJ, Khuntia D. Principles and applications of PET in brain tumors. PET Clinics 2011; 6:131-48.

41.  Cheng KT. [13N] Ammonia. 2005 Dec 5 [Updated 2007 Dec 4]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK23075/

42.  Chopra A. 68Ga-Labeled 2-[3-(1-carboxy-5-{7-[5-carboxy-5-(3-phenyl-2-{3-phenyl-2-[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraazacyclododec-1 l) acetylamino]propionylamino}propionylamino)pentylcarbamoyl]heptanoylamino}pentyl)ureido]pentanedioic acid. 2010 Sep 27 [Updated 2010 Dec 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK51314/

43.  Akdemir E, Tuncel M, Tuncali MC, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S679-S679